Falk Gastro Info 5/2023

Video-on-demand

Symposium 230: STATE-OF-THE-ART MANAGEMENT OF IBD: CURRENT REALITIES AND FUTURE HORIZONS

SESSION II: New and old targets in IBD

Chairs: Stefan Schreiber, Kiel; Andreas Sturm, Berlin

Duration: 83 min

Cell trafficking in IBD: Mechanisms and therapeutic targets

Matthieu Allez, Paris

Treating fibrogenesis in IBD – fiction or future hope?

Florian Rieder, Cleveland

Microbiota – overrated or a new treatment option?

Dirk Haller, Freising

©Falk Foundation e.V., Freiburg. All rights reserved.

Please switch on your loudspeakers!
Link to Falk Mediacenter
Latest research in brief:
Image
Colon to Rectum
Text:
Alayo QA et al, Clin Gastroenterol Hepatol. 2023;21(3):761–70.e13

Inflammatory bowel disease (IBD) is associated with an increased risk of incident acute arterial events (AAEs): In a prospective cohort, there was an increased risk of incident AAEs and premature AAEs in IBD participants. Beyond traditional AAE risk factors, quantifiable indices of IBD disease activity and severity were independent predictors of AAEs.

Link to Falk Mediacenter
Text:
Lam AY et al, Clin Gastroenterol Hepatol. 2023;21(2):487–96.e3

Biopsy of non-tumor sites after biopsy of a colorectal cancer is not associated with metachronous cancers: Metachronous cancers were not significantly associated with biopsy of non-tumor sites after biopsy of the primary cancer in this large case-control study involving more than 14,000 patients.

Link to Falk Mediacenter
Image
Liver and Bile Ducts
Text:
Adraneda C et al, J Hepatol. 2023;78(4):731–41

Critique and systematic review of the utility of hepatitis B core-related antigen (HBcrAg) as biomarker in chronic hepatitis B: New biomarkers could be of great benefit on the way to functional cure of chronic hepatitis B virus infection. Indeed, the hepatitis B core-related antigen (HBcrAg) is a possible candidate as suitable biomarker. A recent critique and systematic review, however, concludes that HBcrAg correlates poorly with HBsAg loss and response to antiviral therapy, and thus has limited clinical utility.

Link to Falk Mediacenter
Text:
Leiskau C et al, J Hepatol. 2023;78(5):971–8

Analysis of acute severe non-A-E hepatitis (NAEH) in children in North-West Germany: NAEH is a rare but serious disease that often leads to acute liver failure. The 2022 global NAEH epidemic has been linked to adenoviral infections. A current evaluation from 2 North-Western German centers (Hanover and Essen) indicates an increasing incidence of NAEH since 2019. However, adenoviral infections played no role, which indicates other potential triggers of similar NAEH cases.

Link to Falk Mediacenter
Text:
Atallah E et al, J Hepatol. 2023;78(5):989–97

Risk of liver fibrosis associated with long-term methotrexate (MTX) therapy may be overestimated: Based on retrospective data, it was concluded that long-term MTX therapy has a significant risk of hepatic fibrosis. However, a recent longitudinal cohort study of patients with rheumatoid arthritis and psoriasis indicated that neither the cumulative MTX dose nor the duration of therapy were associated with increased liver stiffness. In contrast, age and BMI were independently associated with increased liver stiffness.

Link to Falk Mediacenter
Image
Esophagus to Small Intestine
Text:
Lee CYC et al, Lancet Oncol. 2023;24(1):107–16

Endoscopic surveillance in patients at risk of hereditary gastric cancer: Random biopsies enhance the early detection of signet ring cell carcinoma and are complementary to targeted biopsies in surveillance of hereditary diffuse gastric cancer. This sampling method should be the standard of care when performing all surveillance endoscopies for individuals with hereditary diffuse gastric cancer.

Link to Falk Mediacenter
Text:
Fumery M et al, Aliment Pharmacol Ther. 2023;57(4):426–34

Real-world effectiveness of risankizumab for luminal Crohn’s disease (CD): In a cohort of highly refractory patients with luminal CD and multiple prior drug failures including ustekinumab, risankizumab induction provided a clinical response in about 3 out of 4 patients and steroid-free clinical remission in about half of patients.

Link to Falk Mediacenter
Image
Pancreas
Text:
Paniccia A et al, Gastroenterology. 2023;164(1):117–33.e7

Molecular diagnostics for cystic pancreas lesions: Next generation sequencing of 22 genes (PancreaSeq) was not only sensitive and specific for various pancreatic cyst types and advanced neoplasia arising from mucinous cysts in a multi-institutional prospective trial, but also revealed the diversity of genomic alterations seen in pancreatic cysts and their clinical significance.

Link to Falk Mediacenter

Symposium 232

Inflammation of the Upper and Lower GI Tract: Common mechanisms and Treatments or Important Differences?

April 28 – 29, 2023, Bordeaux, France

Program
Online registration

Digital Event

Online Live Event – Symposium 232: Inflammation of the Upper and Lower GI Tract: Common mechanisms and Treatments or Important Differences?

April 28. – 29, 2023

Program
Online registration

Symposium 233

Experimental Hepatology Days

May 18 – 20, 2023, Zurich

Zurich Convention Center, Claridenstr. 5, 8002 Zurich, Switzerland

Program
Online registration

Symposium 234

Mucosal Immunology – A Translational View into the Clinic

July 6 – 8, Potsdam, Germany

Dorint Hotel Sanssouci, Jägerallee 20, 14469 Potsdam, Germany

Program
Online registration

Current Falk literature:

No literature.